全球自然殺手細胞療法市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

自然殺手細胞療法市場規模預計將從 2025 年的 42.6 億美元成長到 2034 年的 126.5 億美元，2026 年至 2034 年的複合年成長率為 12.87%。

受自然殺手 (NK) 細胞在癌症免疫療法中作用日益凸顯的推動，NK 細胞療法市場預計將迎來顯著成長。隨著研究人員不斷揭示 NK 細胞靶向和清除癌細胞的潛力，基於 NK 細胞的治療方法需求激增。細胞療法的創新，包括基因修飾 NK 細胞和聯合治療的開發，正在提高這些治療方法的療效，使其對醫療服務提供者和患者更具吸引力。

此外，個人化醫療的日益普及也影響著NK細胞療法市場。隨著醫療服務提供者尋求根據患者個別情況制定治療方案，對客製化NK細胞療法的需求也在不斷成長。這一趨勢在骨髓惡性腫瘤和固態腫瘤尤其明顯，因為個人化治療可以改善治療效果並減少副作用。

此外，對免疫療法研發的日益重視正在推動NK細胞療法市場的創新。生物製藥公司、研究機構和臨床中心之間的合作正在推動NK細胞技術和治療方法的進步，確保新產品能夠滿足癌症患者不斷變化的需求。醫療專業人員和患者對NK細胞療法潛在益處的認知不斷提高，也促進了市場擴張。總之，自然殺手細胞療法市場預計將迎來強勁成長，其特點是技術進步、注重個人化治療以及致力於改善癌症治療。

目錄

第1章 引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 繪製滲透率和成長前景圖
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 市場問題
• 波特五力分析
• PESTLE分析

4. 全球自然殺手細胞療法市場（依治療方法）

• 市場分析、洞察與預測
• NK細胞標靶抗體
• NK細胞療法

5. 全球自然殺手細胞療法市場（按應用領域分類）

• 市場分析、洞察與預測
• 免疫增生性疾病
• 消化系統疾病
• 癌症
• 其他

6. 全球自然殺手細胞療法市場（以最終用戶分類）

• 市場分析、洞察與預測
• 醫院
• 研究中心和研究所
• 其他

7. 全球自然殺手細胞療法市場（按地區分類）

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商格局（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • NKT Therapeutics Inc
  • Nkarta Therapeutics Inc
  • Nantkwest Inc
  • Innate Pharma SA
  • Glycostem Therapeutics BV
  • Fortress Biotech
  • Fate Therapeutics
  • Celgene Corporation
  • Affimed NV
  • Ziopharm Oncology Inc

The Natural Killer Cells Therapeutics Market size is expected to reach USD 12.65 Billion in 2034 from USD 4.26 Billion (2025) growing at a CAGR of 12.87% during 2026-2034.

The natural killer (NK) cells therapeutics market is poised for significant growth, driven by the increasing recognition of the role of NK cells in cancer immunotherapy. As researchers continue to uncover the potential of NK cells in targeting and eliminating tumor cells, the demand for NK cell-based therapies is surging. Innovations in cell therapy, including the development of engineered NK cells and combination therapies, are enhancing the effectiveness of these treatments, making them more appealing to healthcare providers and patients.

Moreover, the growing emphasis on personalized medicine is influencing the NK cells therapeutics market. As healthcare providers seek to tailor treatments to individual patient profiles, the demand for customized NK cell therapies is rising. This trend is particularly relevant in the context of hematological malignancies and solid tumors, where personalized approaches can improve treatment outcomes and reduce adverse effects.

Furthermore, the increasing focus on research and development in immunotherapy is fostering innovation in the NK cells therapeutics market. Collaborations between bi opharmaceutical companies, research institutions, and clinical centers are driving advancements in NK cell technologies and treatment methodologies, ensuring that new products meet the evolving needs of cancer patients. The growing awareness of the potential benefits of NK cell therapies among healthcare professionals and patients is also contributing to market expansion. In summary, the natural killer cells therapeutics market is set for robust growth, characterized by technological advancements, a focus on personalized treatment approaches, and a commitment to improving cancer care.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapeutics

• NK Cell Directed Antibodies
• NK Cell Therapies

By Application

• Immunoproliferative Disorders
• Gastrointestinal Diseases
• Cancer
• Other

By End User

• Hospitals
• Research Centers & Institutes
• Other

COMPANIES PROFILED

• NKT Therapeutics Inc, Nkarta Therapeutics Inc, Nantkwest Inc, Innate Pharma SA, Glycostem Therapeutics BV, Fortress Biotech, Fate Therapeutics, Celgene Corporation, Affimed NV, Ziopharm Oncology Inc

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET: BY THERAPEUTICS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapeutics
• 4.2. NK Cell Directed Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. NK Cell Therapies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Immunoproliferative Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Gastrointestinal Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Research Centers & Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Therapeutics
  • 7.2.2 By Application
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Therapeutics
  • 7.3.2 By Application
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Therapeutics
  • 7.4.2 By Application
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Therapeutics
  • 7.5.2 By Application
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Therapeutics
  • 7.6.2 By Application
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL NATURAL KILLER CELLS THERAPEUTICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 NKT Therapeutics Inc
  • 9.2.2 Nkarta Therapeutics Inc
  • 9.2.3 Nantkwest Inc
  • 9.2.4 Innate Pharma S.A
  • 9.2.5 Glycostem Therapeutics BV
  • 9.2.6 Fortress Biotech
  • 9.2.7 Fate Therapeutics
  • 9.2.8 Celgene Corporation
  • 9.2.9 Affimed N.V
  • 9.2.10 Ziopharm Oncology Inc